Xifaxan Tablet
NDC Package 50090-2445-0

11-digit billing NDC: 50090244500 · Billing unit: EA · 9 EA per package

Package Information

Xifaxan (rifaximin) tablets is to reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This formulation utilizes a tablet delivery system. Marketed by A-s Medication Solutions, this product is identified by NDC 50090-2445 and is authorized under FDA application NDA021361.

Identification & Billing

NDC Package Code
50090-2445-0
Package Description
9 TABLET in 1 BOTTLE
Product Code
11-Digit Billing Format
50090244500
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
9 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Xifaxan
Non-Proprietary Name
Rifaximin
Substance Name
Rifaximin
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Regulatory & Marketing

Labeler Name
A-s Medication Solutions
Product Type
Human Prescription Drug
FDA Application #
NDA021361
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
07-25-2004
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 50090-2445-0 identifies a specific commercial package of 9 tablet in 1 bottle of Xifaxan, a human prescription drug labeled by A-s Medication Solutions. This product is billed for "EA" each discreet unit and contains an estimated amount of 9 billable units per package. This tablet is formulated for oral use and contains rifaximin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by A-s Medication Solutions on July 25, 2004. The current certification is valid through December 31, 2026.

How is this A-s Medication Solutions product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 50090244500. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 9 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
50090-2445-0
11-Digit CMS (5-4-2)
50090-2445-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.